How effective is effective enough?
- PMID: 37989567
- DOI: 10.1136/jnnp-2023-332311
How effective is effective enough?
Keywords: ALZHEIMER'S DISEASE; STATISTICS.
Conflict of interest statement
Competing interests: TK served on scientific advisory boards for MS International Federation and WHO, BMS, Roche, Janssen, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Roche, Sanofi-Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck. AB serves on scientific advisory boards for Eisai (lecanemab), Biogen (aducanumab) and Roche (gantenerumab), as was a PI for the TRAILBLAZER (Lilly) and ENGAGE (Biogen) studies.
Comment on
-
Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials.J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):2-7. doi: 10.1136/jnnp-2023-331941. J Neurol Neurosurg Psychiatry. 2023. PMID: 37979967 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources